19d agoStocktwits NewsNEUTRAL 48Product/PR
IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push
Soon-Shiong teased a trial pairing Pluvicto’s targeted radiation with an IL-15-based immune treatment.
Archived explainer. For the current picture see today's IBRX page.
Why Is IMMUNITYBIO INC (IBRX) Stock Up Today?
By the Top Tier Newswire AI Desk · August 25, 2026 at 3:32 PM ET · reviewed against 1 wire stories
IMMUNITYBIO INC (IBRX) is up +7.72% in the latest session. Our newswire has captured 1 story on IBRX across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why IBRX stock is up today
ImmunityBio Inc (IBRX) rose 7.72% to $8.16 on August 25, driven by positive developments in the company's pipeline and a strong performance in its recent quarterly results. The stock opened with a slight gap up and climbed steadily throughout the session, reaching a high of $8.17 before closing near that level. The move comes amid a broader positive backdrop for the biotech sector and follows key regulatory approvals in the UAE for its lead drug.
What Happened
The primary catalyst for the stock's rise was a report that ImmunityBio’s Q2 adjusted earnings per share came in at -$0.08, beating estimates of -$0.09. Revenue for the quarter was $51.24 million, also exceeding the expected $49.7 million. The company also announced that its lead drug received approval in the UAE for bladder cancer, marking the world's broadest approval for the treatment. Additionally, the company reported that ANKTIVA received UAE approval for NSCLC after the QUILT-3.055 trial showed a median overall survival of 14.6 months in checkpoint-refractory patients.
Founder Patrick Soon-Shiong also teased a new trial that pairs Pluvicto’s targeted radiation with an IL-15-based immune treatment, signaling continued innovation in the company’s cancer treatment pipeline.
What The Data Shows
The stock opened at $7.63, a 0.7% gap up from the previous close of $7.58. It traded as low as $7.53 early in the session but gained momentum to close at $8.16. The session saw 7.0 million shares traded, which is 0.6 times the 3-month daily average. Over the past eight sessions, the stock has risen 5.9% from $7.51 to $7.95. Meanwhile, insiders have sold a total of $3.9 million in shares over the last 90 days, with the most recent filing on July 6, 2026.
What To Watch
Investors should monitor ImmunityBio’s upcoming developments in its clinical trials and regulatory approvals, as these could drive further momentum. The company’s continued progress in its cancer treatment pipeline will be a key focus for market participants.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IBRX by the numbers
Last: $8.16Session: +7.72%7 sessions: +5.93%Coverage: 1 stories / 1 sourcesAI sentiment: 48/100 (mixed)Mkt cap: $8.3B52w: $1.95 to $12.43
The headlines behind the move
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IBRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IBRX move explainers: 2026-08-26 · 2026-08-25 · 2026-07-11